Long-term Use of First-line Highly Active Antiretroviral Therapy is Not Associated with Carotid Artery Stiffness in Human Immunodeficiency Virus-positive Patients

Overview

Journal Braz J Infect Dis

Specialty Infectious Diseases

Date 2014 May 14

PMID 24819160

Authors

Haohui Zhu

Jianjun Yuan

Yisa Wang

Fan Gao

Xiao Wang

Changhua Wei

Jiyun Chen

Xiaohui Fan

Mei Zhang

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate whether or not highly active antiretroviral therapy is associated with carotid artery stiffness in human immunodeficiency virus-positive patients in Henan Province, China.

Method: Fifty human immunodeficiency virus-positive patients with at least a 5-year history of highly active antiretroviral therapy use and 50 human immunodeficiency virus-positive patients without a history of highly active antiretroviral therapy use were enrolled in this study. Carotid artery intima-media thickness and stiffness were determined by quantitative inter-media thickness and quantitative artery stiffness, respectively.

Results: No statistically significant difference in carotid artery intima-media thickness and stiffness was observed between groups. A significant association between human immunodeficiency virus infection time and carotid artery stiffness was observed, but no significant association between human immunodeficiency virus infection time and intima-media thickness was found. No significant association between intima-media thickness, stiffness, and CD4(+) and CD8(+) T-cell counts were observed.

Conclusion: The first-line highly active antiretroviral therapy currently used in China is not associated with carotid artery stiffness in human immunodeficiency virus-positive patients with good highly active antiretroviral therapy compliance. Human immunodeficiency virus may play a role in the development of atherosclerosis.

References

Boccara F . Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors. AIDS. 2008; 22 Suppl 3:S19-26. DOI: 10.1097/01.aids.0000327512.76126.6e. View

Farrugia P, Lucariello R, Coppola J . Human immunodeficiency virus and atherosclerosis. Cardiol Rev. 2009; 17(5):211-5. DOI: 10.1097/CRD.0b013e3181b151a3. View

Baker J, Lundgren J . Cardiovascular implications from untreated human immunodeficiency virus infection. Eur Heart J. 2011; 32(8):945-51. PMC: 3076665. DOI: 10.1093/eurheartj/ehq483. View

Andrade A, Ladeia A, Netto E, Mascarenhas A, Cotter B, Benson C . Cross-sectional study of endothelial function in HIV-infected patients in Brazil. AIDS Res Hum Retroviruses. 2008; 24(1):27-33. DOI: 10.1089/aid.2006.0281. View

Jerico C, Knobel H, Calvo N, Sorli M, Guelar A, Gimeno-Bayon J . Subclinical carotid atherosclerosis in HIV-infected patients: role of combination antiretroviral therapy. Stroke. 2006; 37(3):812-7. DOI: 10.1161/01.STR.0000204037.26797.7f. View

Lundgren J, Babiker A, El-Sadr W, Emery S, Grund B, Neaton J . Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis. 2008; 197(8):1145-55. DOI: 10.1086/529523. View

van Leuven S, Sankatsing R, Vermeulen J, Kastelein J, Reiss P, Stroes E . Atherosclerotic vascular disease in HIV: it is not just antiretroviral therapy that hurts the heart!. Curr Opin HIV AIDS. 2009; 2(4):324-31. DOI: 10.1097/COH.0b013e3281e38a98. View

Gallet B, Pulik M, Genet P, Chedin P, Hiltgen M . Vascular complications associated with use of HIV protease inhibitors. Lancet. 1998; 351(9120):1958-9. DOI: 10.1016/S0140-6736(05)78643-8. View

Lorenz M, Stephan C, Harmjanz A, Staszewski S, Buehler A, Bickel M . Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis. 2007; 196(2):720-6. DOI: 10.1016/j.atherosclerosis.2006.12.022. View

10.

Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson A, Lambert P . Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008; 300(1):51-9. DOI: 10.1001/jama.300.1.51. View

11.

de Saint Martin L, Vandhuick O, Guillo P, Bellein V, Bressollette L, Roudaut N . Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study). Atherosclerosis. 2005; 185(2):361-7. DOI: 10.1016/j.atherosclerosis.2005.06.049. View

12.

Sudano I, Spieker L, Noll G, Corti R, Weber R, Luscher T . Cardiovascular disease in HIV infection. Am Heart J. 2006; 151(6):1147-55. DOI: 10.1016/j.ahj.2005.07.030. View

13.

Shrestha S, Irvin M, Taylor K, Wiener H, Pajewski N, Haritunians T . A genome-wide association study of carotid atherosclerosis in HIV-infected men. AIDS. 2009; 24(4):583-92. PMC: 3072760. DOI: 10.1097/QAD.0b013e3283353c9e. View

14.

Torriani F, Komarow L, Parker R, Cotter B, Currier J, Dube M . Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol. 2008; 52(7):569-76. PMC: 2603599. DOI: 10.1016/j.jacc.2008.04.049. View

15.

Ross A, Rizk N, ORiordan M, Dogra V, El-Bejjani D, Storer N . Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis. 2009; 49(7):1119-27. PMC: 3895473. DOI: 10.1086/605578. View

16.

Seaberg E, Benning L, Sharrett A, Lazar J, Hodis H, Mack W . Association between human immunodeficiency virus infection and stiffness of the common carotid artery. Stroke. 2010; 41(10):2163-70. PMC: 2972735. DOI: 10.1161/STROKEAHA.110.583856. View

17.

Baker J, Henry W, Patel P, Bush T, Conley L, Mack W . Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort. Clin Infect Dis. 2011; 53(8):826-35. PMC: 3174096. DOI: 10.1093/cid/cir497. View

18.

Dube M, Lipshultz S, Fichtenbaum C, Greenberg R, Schecter A, Fisher S . Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation. 2008; 118(2):e36-40. DOI: 10.1161/CIRCULATIONAHA.107.189625. View

19.

Jeong S, Kim C, Song Y, Baek J, Kim S, Jin S . Low plasma levels of the soluble receptor for advanced glycation end products in HIV-infected patients with subclinical carotid atherosclerosis receiving combined antiretroviral therapy. Atherosclerosis. 2011; 219(2):778-83. DOI: 10.1016/j.atherosclerosis.2011.08.003. View

20.

Anuurad E, Semrad A, Berglund L . Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease. Metab Syndr Relat Disord. 2009; 7(5):401-10. PMC: 3135885. DOI: 10.1089/met.2008.0096. View